0000899243-18-017963.txt : 20180625 0000899243-18-017963.hdr.sgml : 20180625 20180625181527 ACCESSION NUMBER: 0000899243-18-017963 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180625 FILED AS OF DATE: 20180625 DATE AS OF CHANGE: 20180625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Booth Bruce CENTRAL INDEX KEY: 0001451612 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38537 FILM NUMBER: 18917901 MAIL ADDRESS: STREET 1: 890 WINTER STREET STREET 2: SUITE 320 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVROBIO, Inc. CENTRAL INDEX KEY: 0001681087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 810710585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 300, SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7819626030 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 300, SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AvroBio, Inc. DATE OF NAME CHANGE: 20160729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-25 0 0001681087 AVROBIO, Inc. AVRO 0001451612 Booth Bruce C/O AVROBIO, INC. 1 KENDALL SQUARE, BUILDING 300, STE 201 CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2018-06-25 4 C 0 806711 A 806711 I See Footnote Common Stock 2018-06-25 4 C 0 3044579 A 3851290 I See Footnote Common Stock 2018-06-25 4 C 0 905188 A 4756478 I See Footnote Series Seed Preferred Stock 2018-06-25 4 C 0 3333333 0.00 D Common Stock 806711 0 I See footnote Series A Preferred Stock 2018-06-25 4 C 0 12580199 0.00 D Common Stock 3044579 0 I See footnote Series B Preferred Stock 2018-06-25 4 C 0 3740239 0.00 D Common Stock 905188 0 I See footnote Represents the total number of shares of Common Stock received by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), upon the conversion of the Issuer's Series Seed Preferred Stock in connection with the closing of the Issuer's initial public offering. The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. /s/ Bruce Booth 2018-06-25